BridgeBio Pharma (2CL) Q1 2026 Earnings Report
DE:2CL Q1 2026 EPS Results
- Actual EPS
- -EUR 0.75
- Consensus EPS
- -EUR 0.61
- Beat/Miss
- Missed by -EUR 0.14
- One Year Ago EPS
- -EUR 0.79
DE:2CL Q1 2026 Revenue Results
- Actual Revenue
- EUR 173.92M
- Expected Revenue
- EUR 159.21M
- Beat/Miss
- Beat by +EUR 14.71M
- YoY Revenue Growth
- +66.78%
Earnings Announcement Details
- Quarter
- Q1 2026
- Date
- 05/07/2026
- Time
- After Close
- Conference Call
- Thursday, May 7, 2026
DE:2CL Upcoming Earnings
BridgeBio Pharma's next earnings date is estimated for February 25, 2027, based on past reporting schedules.
Q1 2026 Earnings Call Audio
DE:2CL Q1 2026 Earnings Call
0:00 / 0:00
Q1 2026 Earnings Slide Deck
No slide deck is available for this earnings event.
Q1 2026 Earnings Call Summary
No earnings call summary is available for this earnings event.
DE:2CL Earnings History
| Report Date | Fiscal Quarter | Forecast / EPS | Last Year's EPS | EPS YoY Change | Press Release |
|---|---|---|---|---|---|
| Feb 25, 2027 | 2026 (Q4) | -0.53- | -0.89 | ― | ― |
| Oct 29, 2026 | 2026 (Q3) | -0.48-0.38 | -0.85 | 55.79% (+0.47) | |
| Aug 10, 2026 | 2026 (Q2) | -0.52-0.70 | -0.85 | 17.89% (+0.15) | |
| May 07, 2026 | 2026 (Q1) | -0.61-0.75 | -0.79 | 4.55% (+0.04) | |
| Feb 24, 2026 | 2025 (Q4) | -0.64-0.89 | -1.25 | 28.57% (+0.36) | |
| Oct 29, 2025 | 2025 (Q3) | -0.80-0.85 | -0.77 | -10.47% (-0.08) | |
| Aug 05, 2025 | 2025 (Q2) | -0.71-0.85 | -0.35 | -143.59% (-0.50) | |
| Apr 29, 2025 | 2025 (Q1) | -0.82-0.79 | -0.18 | -340.00% (-0.61) | |
| Feb 20, 2025 | 2024 (Q4) | -1.00-1.25 | -0.86 | -45.83% (-0.39) | |
| Nov 12, 2024 | 2024 (Q3) | -0.90-0.77 | -0.97 | 20.37% (+0.20) |
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat Missed
